FDA Urged To Revise Manufacturing Reg To Increase Flexibility For OTCs
This article was originally published in The Tan Sheet
Executive Summary
Drug firms have more flexibility changing production protocols for over-the-counter drugs than pharmaceuticals, but the industry would benefit if FDA regulations allowed supplements for OTC products' chemistry, manufacturing and controls to be done without prior approval, an industry representative says